Case 3: 70-Year-Old Former Smoker with Stage IIIB NSCLC with PD-L1 10%

Opinion
Video

Dr. Gregory Gan introduces Case 2, involving a 70-year-old former smoker with Stage IIIB NSCLC and a PD-L1 level of 10%, prompting discussion with emphasis on the importance of shared decision-making with the patient and their caregivers.

CN_KC_SS_Seg15
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
      Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
      A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
      Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
      6 experts are featured in this series.
      Future Therapies for ALK+ Metastatic NSCLC
      6 experts are featured in this series.
      Evaluating ALK Inhibitors in Treatment Sequencing and Testing
      6 experts are featured in this series.
      Treatment Strategies in Disease Progression in ALK+ NSCLC
      6 experts are featured in this series.
      Patient Factors Considered when Choosing Treatment Selection
      6 experts are featured in this series.
      KRAS+ NSCLC: Treatment Management Strategies
      6 experts are featured in this series.
      Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
      6 experts are featured in this series.
      KRAS G12 Inhibitor Treatment Options
      6 experts are featured in this series.
      Clinical Experience of Lorlatinib ALK+ NSCLC Patients
      Related Content
      The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

      Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

      Roman Fabbricatore
      March 30th 2025
      Article

      The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Improving NSCLC Surgery Recovery After Climate Disaster Exposure

      Leticia Nogueira, PhD, MPH
      March 31st 2025
      Podcast

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

      Russ Conroy
      March 28th 2025
      Article

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      Tim Cortese
      March 27th 2025
      Article

      CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Tim Cortese
      March 25th 2025
      Article

      In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.